Trial · NCT03152552
Outcomes26
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
21 to 26 of 26
Download this page as JSON| Type | Outcome | Time frame | Population | Units | Measured as |
|---|---|---|---|---|---|
| SECONDARY | Number of Participants With New York Heart Association (NYHA) Class I, II, II or IV | Baseline, Week 12, Week 36 | The Full Analysis Set (FAS) consisted of all randomized patients who were not mis-randomized. LIK066 doses and placebo arms were considered per study objective. Due to early termination of the study, only the data shown was available. | Participants | COUNT_OF_PARTICIPANTS |
| SECONDARY | Number of Participants With Change From Baseline in New York Heart Association (NYHA) Class at Week 12 and 36 | Week 12, Week 36 | The Full Analysis Set (FAS) consisted of all randomized patients who were not mis-randomized. LIK066 doses and placebo arms were considered per study objective. Due to early termination of the study, only the data shown was available. | Participants | COUNT_OF_PARTICIPANTS |
| SECONDARY | Change From Baseline in N-terminal Pro B-type Natriuretic Peptide (NT-proBNP) at Week 36 | Baseline, Week 36 | The Full Analysis Set (FAS) consisted of all randomized patients who were not mis-randomized. LIK066 doses and placebo arms are considered per study objective. Due to early termination of the study, only the data shown was available. | ratio | GEOMETRIC_MEAN |
| SECONDARY | Change From Baseline in 24 Hour Urinary Calcium Excretion at Weeks 12 and 36 | Baseline, Week 12, Week 36 | Safety Set: All patients who received at least 1 dose of double-blind study drug \& included patients who participated in sub-study. Due to early termination of study, only data shown was available. 'Overall Number of Participants Analyzed' = enrolled in 24h urine collection sub-study. 'Number Analyzed '= number of participants with data available | millimoles per day (mmol/d) | MEAN |
| SECONDARY | 24 Hour Urinary Phosphate Excretion at Weeks 12 and 36 | Baseline, Week 12, Week 36 | The Safety Set (SAF), which consisted of all patients who received at least one dose of double-blind study drug, was considered. The analysis included patients who participated in the 24h urine collection sub-study. Due to early termination of the study, only the data shown was available. | millimoles per day (mmol/d) | MEAN |
| SECONDARY | Change From Baseline in Bone Mineral Density (BMD) at Weeks 12 and 36 | Baseline, Week 12, Week 36 | The Safety Set (SAF), which consisted of all patients who received at least one dose of double-blind study drug, was considered. The analysis included participants who participated in the DXA sub-study. Due to early termination of the study, only the data shown was available. | grams (g) | MEAN |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT03152552/outcomes?page=2